Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global...
Covered in this story
What has happened since
- Viatris is up 5.5% since this was published, 12 days ago.
- Pacira Biosciences Inc is down 0.1% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $VTRS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Viatris →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.